Chemotherapy for Lung Cancer Based on Drug Resistance Testing
Author Information
Author(s): D.W. Wilbur, E.S. Camacho, D.A. Hilliard, P.L. Dill, L.M. Weisenthal
Primary Institution: Pettis Memorial Veterans Hospital, Loma Linda
Hypothesis
Can an in vitro drug resistance assay improve chemotherapy outcomes for non-small cell lung carcinoma?
Conclusion
The study suggests that using an in vitro drug resistance assay can help identify patients who are more likely to respond to chemotherapy.
Supporting Evidence
- Thirty-five assays were successful out of 45 attempted.
- Nine patients had a partial response to treatment, resulting in a 36% response rate.
- The median survival for all patients was 202 days.
Takeaway
Doctors tested cancer samples from patients to see which drugs would work best, and it helped some patients get better treatment.
Methodology
Patients with untreated non-small cell lung cancer were tested for drug sensitivity using the DiSC assay, and treatment was based on the results.
Potential Biases
Potential bias due to the small number of patients and the subjective nature of some assessments.
Limitations
The study had a small sample size and included patients in poor health, which may limit the generalizability of the results.
Participant Demographics
Patients were primarily older adults with advanced non-small cell lung cancer, many in poor general health.
Statistical Information
P-Value
0.005
Confidence Interval
95% confidence interval = 17-55%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website